Century Therapeutics Inc is a biotechnology company focused on developing stem cell-derived cellular therapies for the treatment of cancer and other serious diseases
The company leverages innovative technologies in induced pluripotent stem cells (iPSCs) to create immune cells that are engineered to target and destroy tumors while minimizing damage to healthy tissues. By advancing its research and clinical programs, Century aims to transform the landscape of cancer treatment, providing more effective and personalized therapeutic options for patients.
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D activities. Acquisition of Clade Therapeutics enhances pipeline with iPSC-focused programs.
IPSC stock results show that Century Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
IN8bio (NASDAQINAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these cells to effectively target and eliminate cancer cells in both solid and hematological tumors.
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps & Tech-heavy QQQ ETF by 11.4% (MTD)
Truist Securities raised the price target for Church & Dwight Co., Inc. (NYSECHD) from $95 to $105. Truist Securities analyst Bill Chappell upgraded the stock from Hold to Buy. Church & Dwight shares gained 0.5% to close at $93.30 on Friday.
